1032767-83-1

Upstream product

• 1032767-79-5 (S)-6-benzyloxycarbonylamino-2-(2-oxooxazolidinesulfonylamino)hexanoic acid benzyl ester 
• 6366-70-7 N^ε-carbobenzoxy-L-lysine benzyl ester hydrochloride 
• 37736-82-6 (S)-2-tert-butoxycarbonylamino-3-cyclohexylpropionic acid 
• 32511-34-5 (R)-Bornylamine 
• 1032767-80-8 [(S)-2-cyclohexyl-1-((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylcarbamoyl)ethyl]carbamic acid tert-butyl ester 

Downstream Products

• 1032767-05-7 (S)-6-amino-2-{[(S)-2-cyclohexyl-1-((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylcarbamoyl)ethylsulfamidyl]}hexanoic acid 

Relevant academic research and scientific papers

Sulfamide as Zinc Binding Motif in Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)

Previously disclosed TAFIa inhibitors having a urea zinc-binding motif were used as the starting point for the development of a novel class of highly potent inhibitors having a sulfamide zinc-binding motif. High-resolution X-ray cocrystal structures were used to optimize the structures and reveal a highly unusual sulfamide configuration. A selected sulfamide was profiled in vitro and in vivo and displayed a promising ADMET profile.

UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa

The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.